SironRx Raises $3.4 Million Early Stage Venture Capital Round
Cleveland, OH--SironRX, a spinoff from Juventas Therapeutics focused on wound healing, closed a $3.4 million Series A early stage venture capital investment round. Investors in the round included Fletcher Spaght, North Coast Angel Fund, Early Stage Partners, JumpStart, and Glengary.
SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and the Cleveland Clinic Foundation that promote wound repaid and prevent the scarring of dermal wounds. Read more...
Find Out More About ESP